Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2016 | Effect of cabozantinib on quality of life in renal cell carcinoma

Sumanta Pal • 7 Oct 2016
ESMO 2016
Genitourinary Cancer Kidney Cancer Cabozantinib

Sumanta Kumar Pal, MD of City of Hope , Duarte, CA shares the new research in renal cell carcinoma he is most excited about at the European Society for Molecular Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. He discusses data he is presenting at this congress on quality of life in the context of cabozantinib treatment (NCT01865747). Dr Pal describes the step-wise increase in quality of life seen during the course of therapy with this second-line agent in renal cell carcinoma, and argues why he prefers cabozantinib over other treatment options.

More from Sumanta Pal

1:12
Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials
Sumanta Pal • 3 Jun 2016
1:15
Treating advanced/metastatic urothelial carcinoma: recent developments in the BGJ398 clinical trial
Sumanta Pal • 3 Jun 2016

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals